Vnitr Lek 2016, 62(Suppl 3):99-102

The endocannabinoid system and bone

Mikuláš Pura1,2,3, Peter Vaňuga1,*
1 Národný endokrinologický a diabetologický ústav, Ľubochňa, Slovenská republika
2 Endokrinologická ambulancia, Ružomberok, Slovenská republika
3 Endokrinologická ambulancia, Poliklinika Novamed, Banská Bystrica, Slovenská republika

Recent studies suggest an important role for the skeletal endocannabinoid system in the regulation of bone mass in both physiological and pathological conditions. Both major endocannabinoids (anandamid and 2-arachidonoylglycerol), endocannabinoid receptors - CB1-receptor (CB1R) a CB2-receptor (CB2R) and the endocannabinoid metabolizing enzymes are present or expressed in osteoblasts and osteoclasts. Previous studies identified multiple risk and protective variants of CNR2 gene dealing with the relationship to bone density and/or osteoporosis. Selective CB1R/ CB2R-inverse agonists/antagonists and CB2R-inverse agonists/antagonists are candidates for prevention of bone mass loss and combined antiresorptive and anabolic therapy for osteoporosis.

Keywords: cannabinoid receptors; endocannabinoids; marijuana; osteoporosis

Received: September 6, 2016; Accepted: September 17, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pura M, Vaňuga P. The endocannabinoid system and bone. Vnitr Lek. 2016;62(Supplementum 3):99-102.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bab I, Zimmer A, Melamed E. Cannabinoids and skeleton: from marijuana to reversal of bone loss. Ann Med 2009; 41(8): 560-567. Dostupné z DOI: <http://dx.doi.org/10.1080/07853890903121025>. Go to original source... Go to PubMed...
    2. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48(16): 5059-5087. Go to original source... Go to PubMed...
    3. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147(Suppl 1): S163-S171. Go to original source... Go to PubMed...
    4. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007; 9(4): 413-430. Go to original source...
    5. Marx J. Drug development. Drugs inspired by a drug. Science 2006; 311(5759): 322-325. Go to original source... Go to PubMed...
    6. Fattore L (ed). Canabinoids in neurologic and mental disease. Elsevier: San Diego 2015. ISBN 978-0124170414
    7. Köhler FE. Medizinal-Pflanzen in naturgetreuen Abbildungen mit kurz erläuterndem Texte. Gera-Untermhaus: 1887. Dostupné z WWW: Dostupné z DOI: <http://www.botanicus.org/item/31753002839139>.
    8. Raphael B, Gabet Y. The skeletal endocannabinoid system: clinical and experimental insights. J Basic Clin Physiol Pharmacol 2016; 27(3): 237-245. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2015-0073>. Go to original source... Go to PubMed...
    9. Ledent C, Valverde O, Cossu G et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283(5400): 401-404. Go to original source... Go to PubMed...
    10. Tam J, Ofek O, Fride E et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006; 70(3): 786-792. Go to original source... Go to PubMed...
    11. Idris AI, van't Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11(7): 774-779. Go to original source... Go to PubMed...
    12. Bab I, Ofek O, Tam J et al. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008; 20(Suppl 1): S69-S74. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2826.2008.01675.x>. Go to original source... Go to PubMed...
    13. Ofek O, Karsak M, Leclerc N et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci 2006; 103(3): 696-701. Go to original source... Go to PubMed...
    14. Brown JP, Delmas PD, Malaval L et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 1(8386): 1091-1093. Go to original source... Go to PubMed...
    15. Sophocleous A, Idris AI, Ralston SH. Genetic background modifies the effects of type 2 cannabinoid receptor deficiency on bone mass and bone turnover. Calcif Tissue Int 2014; 94(3): 259-268. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223-013-9793-8>. Go to original source... Go to PubMed...
    16. Whyte LS, Rynerg E, Sims NA et al. The putative cannabinoid receptor GPR55 affects osteclast function in vitro and bone mass in vivo. Proc Natl Acad Sci 2009; 106(38): 16511-16516. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.0902743106>. Go to original source... Go to PubMed...
    17. Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152(7): 1092-1101. Go to original source... Go to PubMed...
    18. Begg M, Pacher P, Batkai S et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106(2): 133-145. Go to original source... Go to PubMed...
    19. Idris AI. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Curr Neuropharmacol 2010; 8(3): 243-253. Dostupné z DOI: <http://dx.doi.org/10.2174/157015910792246173>. Go to original source... Go to PubMed...
    20. Idris AI, Sophocleous A, Landao-Bassonga E et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009; 10(2): 139-147. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2009.07.006>. Go to original source... Go to PubMed...
    21. Idris AI, Sophocleous A, Landao-Bassonga E et al. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008; 149(11): 5619-5626. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2008-0150>. Go to original source... Go to PubMed...
    22. Devoto M, Shimoya K, Caminis J et al. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet 1998; 6(2): 151-157. Go to original source... Go to PubMed...
    23. Devoto M, Specchia C, Li HH et al. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet 2001; 10(21): 2447-2452. Go to original source... Go to PubMed...
    24. Devoto M, Spotila LD, Stabley DL et al. Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet 2005; 13(6): 781-788. Go to original source... Go to PubMed...
    25. Valdéz-Flores M, Casas-Avila L, Ponce de León-Suárez V. Genetic diseases related wih osteoporosis. In: Valdéz-Flores M (ed). Topics in osteoporosis. In Tech. Dostupné z WWW: <http://www.intechopen.com/books/howtoreference/topics-in-osteoporosis/genetic-diseases-related-with-osteoporosis>.
    26. Karsak M, Cohen-Solal M, Freudenberg J et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005; 14(22): 3389-3396. Go to original source... Go to PubMed...
    27. Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 2007; 19(5): 791-801. Go to original source...
    28. Zhang C, Ma J, Chen G et al. Evaluation of common variants in CNR2 gene for bone mineral density and osteoporosis susceptibility in postmenopausal women of Han Chinese. Osteoporosis Int 2015; 26(12): 2803-2810. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-015-3195-x>. Go to original source... Go to PubMed...
    29. Woo JH, Kim H, Kim JH et al. Cannabinoid receptor genepolymorphisms and bone mineral density in Korean postmeonpausal women. Menopause 2015; 22(5): 512-519. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000339>. Go to original source... Go to PubMed...
    30. Smoum R, Baraghithy S, Chourasia M et al. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: an inverse relationship between binding affinity and biological potency. Proc Natl Acad Sci USA 2015; 112(28): 8774-8779. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1503395112>. Go to original source... Go to PubMed...
    31. Raphael B, Gabet Y. The skeletal endocannabinoid system: clinical and experimental insights. J Basic Clin Physiol Pharmacol 2016; 27(3): 237-245. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2015-0073>. Go to original source... Go to PubMed...
    32. Nutt D, King LA, Saulsbury W et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369(9566): 1047-1053. Go to original source... Go to PubMed...
    33. Nutt DJ, King LA, Phillips LD et al. Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376 (9752): 1558-1565. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(10)61462-6>. Go to original source... Go to PubMed...
    34. Hanuš LO, Kotrba Š. Nad léčivými jointy s Lumírem Hanušem. Britské listy [18-09-2008]. Dostupné z WWW: <http://blisty.cz/art/42801.html>.
    35. Holland J (ed). Tráva. Kompletní průvodce světem marihuany v medicíně, vědě, kultuře a politice. Pragma: Praha 2014. ISBN 978-80-7349-408-7
    36. Martínez-Pinilla E, Rabal O, Reyes-Resina I et al. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay. J Pharmacol Exp Ther 2016; 358(3): 580-587. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.116.234948>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.